RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Modality (RNA interference, Antisense therapy, Messenger RNA, Oligonucleotide, non-antisense, non-RNAi), By Phase (Phase I, Phase II, Phase III, Phase IV), By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others), By Region, and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 2.62 billion

CAGR (2023-2028)

5.06%

Fastest Growing Segment

Rare Diseases

Largest Market

North America

Market Overview

Global RNA Therapy Clinical Trials Market has valued at USD 2.62 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 5.06% through 2028. RNA therapy is a cutting-edge field of medical research, has emerged as a promising avenue for the development of innovative treatments for a wide range of diseases. This novel approach harnesses the power of ribonucleic acid (RNA) to modulate gene expression and provide therapeutic benefits. The global RNA therapy clinical trials market has gained significant traction in recent years, revolutionizing the landscape of healthcare and offering potential solutions for previously untreatable conditions. RNA therapy operates on the principle of utilizing RNA molecules, including messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs), to target specific genes and regulate their activity. This precision-based approach holds immense potential for addressing genetic disorders, infectious diseases, cancer, and even rare conditions that lack effective treatment options. Unlike traditional pharmaceuticals, RNA therapies aim to intervene at the genetic level, potentially providing more targeted and personalized treatments. The RNA therapy clinical trials market has witnessed a remarkable surge in activity, driven by advances in biotechnology, improved understanding of RNA biology, and the success of pioneering RNA-based treatments like mRNA vaccines. Clinical trials serve as critical conduits for testing the safety and efficacy of these groundbreaking therapies before they can be approved for widespread use. These trials, often involving collaboration between academia, pharmaceutical companies, and research organizations, play an instrumental role in shaping the future of RNA-based medicine. One of the most notable breakthroughs in the RNA therapy clinical trials market has been the development and rapid deployment of mRNA vaccines against infectious diseases. The unprecedented success of mRNA-based COVID-19 vaccines has showcased the potential of this technology to mount a robust immune response without traditional vaccine components. This achievement has not only demonstrated the viability of mRNA therapies but has also accelerated research and investment in other RNA-based treatments. In the realm of genetic disorders, RNA therapy has shown promise in treating conditions that arise from single-gene mutations. For instance, ASOs have been investigated for their potential to modulate gene expression in diseases like Duchenne muscular dystrophy and spinal muscular atrophy. These trials represent a beacon of hope for patients and families affected by these devastating conditions, offering the prospect of targeted treatments that could improve quality of life and even extend lifespan. Despite the immense potential, the RNA therapy clinical trials market also faces challenges. Delivery methods, off-target effects, and manufacturing scalability are some of the hurdles that researchers and developers must overcome to ensure the success of RNA therapies. Additionally, the regulatory landscape for these therapies continues to evolve, necessitating close collaboration between industry stakeholders and regulatory agencies to ensure patient safety and facilitate timely approvals.

In conclusion, the global RNA therapy clinical trials market stands at the forefront of medical innovation, holding the promise to revolutionize healthcare by providing novel treatments for a diverse array of diseases. The success of mRNA vaccines and ongoing advancements in RNA-based therapies underscore the transformative potential of this field. As research continues and clinical trials progress, RNA therapy has the potential to reshape the treatment landscape, offering hope to countless patients and fundamentally changing the way we approach medical care.

Key Market Drivers

Rapid Advancement in RNA Technology

Rapid advances in RNA technology have significantly propelled the Global RNA Therapy Clinical Trials Market, revolutionizing the landscape of medical research and healthcare. These breakthroughs are driving the development of innovative RNA-based therapies with the potential to address a wide spectrum of diseases and conditions. One pivotal advancement is the refinement of RNA synthesis techniques. Researchers have developed more precise and efficient methods for synthesizing various types of RNA molecules, including messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs). These techniques allow for the creation of highly specific RNA sequences tailored to target particular genes or molecular pathways implicated in diseases. Furthermore, advancements in RNA modification have enhanced the stability and functionality of therapeutic RNA molecules. Researchers have developed strategies to modify the chemical structure of RNA, increasing their resistance to degradation and improving their biodistribution within the body. This has resulted in prolonged therapeutic effects and reduced the frequency of dosing, a crucial factor in enhancing patient compliance and overall treatment efficacy. Delivery systems have also undergone remarkable innovation. Overcoming the challenge of efficiently delivering RNA molecules to target cells, researchers have developed nanoparticle-based delivery systems and lipid nanoparticles that protect the fragile RNA cargo during transit and facilitate its entry into cells. These advancements have led to improved cellular uptake, reduced off-target effects, and enhanced therapeutic outcomes. Moreover, advances in RNA technology have enabled the development of novel combination therapies. By combining different types of RNA molecules or integrating RNA therapies with other treatment modalities, researchers are exploring synergistic effects that could lead to more potent and comprehensive therapeutic interventions. These rapid advances in RNA technology have not only paved the way for groundbreaking treatments but have also streamlined the clinical trial process. The increased stability and precision of RNA molecules, coupled with improved delivery systems, contribute to the enhanced safety and efficacy of RNA therapies in clinical settings. This has prompted greater interest and investment from pharmaceutical companies, biotech firms, and research institutions, fostering a collaborative environment that accelerates the progression of RNA therapy clinical trials.

Success of mRNA Vaccines

The resounding success of mRNA vaccines has reverberated across the Global RNA Therapy Clinical Trials Market, catalyzing a paradigm shift in medical research and therapeutic development. The unprecedented achievements of mRNA vaccines, particularly in the context of addressing the COVID-19 pandemic, have illuminated the immense potential of RNA-based therapies and spurred accelerated advancements in the field. mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, demonstrated remarkable efficacy in generating potent immune responses against the SARS-CoV-2 virus. These vaccines harnessed the inherent capabilities of mRNA to instruct cells to produce a harmless piece of the virus (the spike protein), stimulating an immune response that confers protection against the actual virus. The rapid development, regulatory approval, and global deployment of these vaccines underscored the agility and adaptability of mRNA technology. This success has had profound implications for the Global RNA Therapy Clinical Trials Market. Firstly, it has bolstered investor confidence and attracted significant funding to RNA-based therapies. The validated efficacy of mRNA vaccines has drawn attention to the broader applications of mRNA technology beyond infectious diseases, including its potential to target various genetic disorders, cancers, and rare diseases. Secondly, the expedited development and approval of mRNA vaccines have set a precedent for streamlined regulatory pathways for RNA-based therapies. Regulatory agencies recognized the urgency and potential of mRNA technology, leading to an environment that is more receptive to innovative RNA therapies. This has expedited the initiation and progress of clinical trials for RNA-based treatments, allowing researchers to navigate regulatory processes more efficiently.

Furthermore, the success of mRNA vaccines has ignited collaboration and knowledge-sharing among researchers, pharmaceutical companies, and academic institutions. The rapid dissemination of findings and data from mRNA vaccine trials has accelerated the development of other RNA therapies by providing valuable insights into dosage, delivery methods, and safety profiles.

Technological Innovation

Technological innovation stands as a driving force within the Global RNA Therapy Clinical Trials Market, ushering in transformative advancements that are reshaping the landscape of medical research and therapeutic development. These innovations span a range of areas critical to the success of RNA-based therapies, and they hold the potential to overcome challenges, enhance efficacy, and accelerate the translation of cutting-edge science into tangible clinical applications. One pivotal aspect of technological innovation is the refinement of drug delivery systems for RNA therapies. Researchers have developed ingenious nanoparticle formulations and lipid-based carriers that encapsulate fragile RNA molecules, shielding them from degradation and facilitating their targeted delivery to specific cells or tissues. This breakthrough has ameliorated one of the primary challenges of RNA therapy—efficiently navigating the body and ensuring the therapeutic payload reaches its intended destination. Moreover, advancements in RNA modification techniques have been instrumental. These innovations allow researchers to design modified RNA molecules with enhanced stability, reduced immune system recognition, and improved binding to their intended targets. Such modifications not only extend the half-life of RNA therapies in circulation but also enhance their efficacy and minimize off-target effects, making them safer and more potent treatment options. Technological innovation has also yielded sophisticated tools for designing and optimizing RNA sequences. Computational algorithms and artificial intelligence-driven platforms enable rapid and accurate prediction of RNA interactions, aiding researchers in selecting the most effective RNA sequences for therapeutic applications. This accelerates the discovery phase, enabling more efficient identification of RNA molecules with high therapeutic potential.

Furthermore, the convergence of gene editing technologies, such as CRISPR-Cas9, with RNA therapies opens new vistas for treating genetic disorders. Researchers can now harness the precision of CRISPR to correct or modify specific genes, while RNA molecules guide and enhance the editing process. This synergy expands the capabilities of RNA therapies, offering a dual approach that addresses genetic defects at both the transcriptional and translational levels. These technological innovations have catalyzed the development of combination therapies, wherein different RNA molecules or RNA-based therapies are synergistically employed to maximize therapeutic impact. By leveraging the strengths of multiple RNA strategies, researchers can create more comprehensive treatment regimens that target multiple aspects of disease pathways, potentially leading to improved clinical outcomes. In conclusion, technological innovation is a driving force shaping the Global RNA Therapy Clinical Trials Market. These advancements in drug delivery, RNA modification, computational design, gene editing, and combination therapies are revolutionizing the landscape of RNA-based therapeutics. By overcoming challenges, enhancing precision, and expanding therapeutic possibilities, these innovations are propelling the field forward, offering new hope for patients and opening doors to innovative treatments for a myriad of diseases.


Key Market Challenges

Delivery Challenges

Delivery challenges are a critical aspect of the Global RNA Therapy Clinical Trials Market, representing a complex hurdle that researchers and developers must overcome to ensure the safe and effective administration of RNA-based therapies. These challenges center around the successful and targeted delivery of RNA molecules to specific cells or tissues within the body, a fundamental requirement for achieving the desired therapeutic outcomes. RNA molecules, due to their inherent properties, face numerous obstacles when administered in their raw form. They are vulnerable to degradation by enzymes and can trigger immune responses, potentially limiting their therapeutic potential. Furthermore, RNA molecules have a relatively short half-life within the body, necessitating repeated dosing to maintain therapeutic levels. Efficient delivery is crucial to ensure that therapeutic RNA reaches its intended target while minimizing off-target effects and potential toxicity. Researchers are tasked with developing delivery strategies that protect RNA molecules during transit, enable their uptake by target cells, and facilitate their release at the desired site of action. To address these challenges, innovative delivery systems have been developed. Nanoparticle-based formulations, such as lipid nanoparticles and polymer-based carriers, are designed to encapsulate RNA molecules, shielding them from degradation and enhancing their stability in circulation. These nanoparticles can be engineered to exhibit favorable biodistribution and cellular uptake properties, improving the chances of RNA molecules reaching their intended targets.

Additionally, researchers explore targeting strategies that guide nanoparticles to specific cells or tissues. This can involve attaching ligands or antibodies to nanoparticles, allowing them to bind to cell surface receptors and facilitating internalization into the target cells. Such targeted delivery approaches enhance the specificity of treatment and minimize unintended effects on non-targeted tissues. However, delivery challenges are complex and multifaceted. Factors such as the size, charge, and surface properties of nanoparticles, as well as the choice of targeting ligands, all influence the success of RNA delivery. Moreover, different diseases and tissue types may require tailored delivery solutions, further complicating the development process.

Stability and Half-Life

Stability and half-life are crucial considerations in the Global RNA Therapy Clinical Trials Market, playing a pivotal role in determining the effectiveness, safety, and practicality of RNA-based therapies. These factors directly impact the therapeutic potential of RNA molecules and their ability to deliver sustained and desired outcomes. RNA molecules are inherently fragile and susceptible to degradation by various cellular and extracellular factors. Ensuring the stability of RNA therapies during storage, transportation, and administration is essential to maintain their structural integrity and functional properties. Stability concerns are particularly significant for long-term storage and distribution of RNA-based therapies, as degradation can compromise their efficacy and render them ineffective. Furthermore, the half-life of RNA molecules in the body influences their duration of action and the dosing frequency required to achieve therapeutic effects. RNA molecules typically have a shorter half-life compared to traditional small molecule drugs or proteins. This can necessitate frequent dosing regimens, which may be inconvenient for patients and potentially lead to fluctuations in therapeutic levels over time.

Key Market Trends

Personalized and Precision Medicine

Personalized and precision medicine represents a transformative approach within the Global RNA Therapy Clinical Trials Market, heralding a new era of tailored treatments that leverage individual genetic information to enhance therapeutic efficacy and minimize adverse effects. This paradigm shift is reshaping the landscape of medical research and clinical trials, particularly in the realm of RNA-based therapies. Personalized medicine involves tailoring medical interventions to the unique characteristics of each patient. In the context of RNA therapy clinical trials, personalized medicine seeks to identify specific genetic mutations or molecular profiles associated with a disease and then design RNA-based treatments that precisely target these genetic aberrations. This approach aims to maximize therapeutic benefits while minimizing potential harm to healthy tissues. Precision medicine takes this concept further by using advanced diagnostics and genetic profiling to not only identify genetic variations but also predict how an individual will respond to a particular treatment. In the context of RNA therapy clinical trials, precision medicine may involve analyzing a patient's genetic makeup to determine the most suitable RNA molecule or therapeutic strategy for their specific condition. RNA therapies are particularly well-suited for personalized and precision medicine approaches due to their ability to selectively target genes or molecular pathways. Clinical trials are increasingly incorporating genetic sequencing and profiling to identify patient populations that are most likely to respond favorably to RNA-based treatments. By understanding the genetic basis of a disease and tailoring therapies accordingly, researchers aim to improve treatment outcomes and minimize the risk of adverse reactions. Personalized and precision medicine also have implications for trial design and patient recruitment. Clinical trials can be designed to enroll patients whose genetic profiles align with the mechanisms of the RNA therapy being tested. This approach enhances the likelihood of observing meaningful therapeutic effects in the trial participants. The integration of personalized and precision medicine in RNA therapy clinical trials has the potential to accelerate the development of effective treatments. It allows for more targeted and efficient clinical trials, as well as optimized treatment regimens that are better aligned with the individual needs of patients. As genetic sequencing technologies become more accessible and affordable, the application of personalized and precision medicine in RNA therapy clinical trials is expected to become increasingly prevalent, paving the way for more effective and patient-centric treatments.

Gene Editing Integration

Gene editing integration represents a groundbreaking frontier within the Global RNA Therapy Clinical Trials Market, where the convergence of RNA-based therapies and advanced gene editing technologies is unlocking new avenues for targeted and precise interventions at the genetic level. This integration holds the potential to revolutionize the treatment of genetic disorders and other diseases by directly modifying the underlying genetic code. At the heart of gene editing integration is the utilization of RNA molecules to guide and enhance gene editing processes. One of the most prominent gene editing technologies is CRISPR-Cas9, which employs a RNA guide molecule to direct the Cas9 enzyme to a specific genomic location, where it induces precise DNA modifications. In the context of RNA therapy clinical trials, researchers are exploring how these guide RNA molecules can be strategically designed to edit or correct genetic mutations responsible for various diseases.

Segmental Insights

Modality Insights

In 2022, the RNA Therapy Clinical Trials Market was dominated by the messenger RNA segment and is predicted to continue expanding over the coming years. This is due to use of mRNA-based vaccinations. Due to the efficacy of these mRNA vaccines, mRNA technology has gained attention and shown promise in the fight against infectious diseases. Moreover, there are several potential uses for mRNA treatments in a variety of illness states. They can be used to encode particular proteins that make therapeutic antibodies, activate an immunological response, or restore protein function.

Phase Insights

In 2022, the RNA Therapy Clinical Trials Market was dominated by phase II segment and is predicted to continue expanding over the coming years. This is due to rising investment in R&D and an increasing number of non-industry-sponsored and industry-sponsored clinical trials in phase II are major contributing factors to the segment's growth. Phase 2 studies enable the determination of the ideal dose and dosing regimen for RNA therapies.

Download Free Sample Report

Regional Insights

In 2022, the RNA Therapy Clinical Trials Market was dominated by North America segment and is predicted to continue expanding over the coming years. This is ascribed due to the early adoption of RNA therapies, robust research infrastructure, regulatory environment, and strong biotechnology and pharmaceutical industry. North America has been at the forefront of the development and early adoption of RNA therapies.

Recent Developments

·    In December 2022, Moderna & Merck mentioned the phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940 a personalized mRNA cancer vaccine with KEYTRUDA combination. It is an mRNA cancer vaccine for melanoma stage III/IV patient treatment.

·         In March 2021, IQVIA Company announced the collaboration with Janssen Research & Development, LLC for Phase 3 COVID-19 vaccine clinical trials.

Key Market Players

·              IQVIA

·              ICON Plc

·              Laboratory Corporation of America Holdings

·              Charles River Laboratories International, Inc.

·              PAREXEL International Corp.

·              Syneos Health

·              Medpace Holdings, Inc.

·              Novotech

·              Veristat, LLC.

·              Veristat, LLC.

 By Modality

  By Phase

  By Therapeutic Areas

By Region
  • RNA interference
  • Antisense therapy Messenger RNA
  • Oligonucleotide
  • Non-antisense
  • Non-RNAi
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  •  
  • Rare Diseases
  • Anti-infective
  • Anticancer
  • Neurological
  • Alimentary/Metabolic
  • Musculoskeletal
  • Cardiovascular Respiratory
  • Sensory
  • Others
  • North America
  • Asia Pacific
  • Europe
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global RNA Therapy Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Global RNA Therapy Clinical Trials Market, By Modality:

·         RNA interference

·         Antisense therapy Messenger RNA

·         Oligonucleotide

·         Non-antisense

·         Non-RNAi

  • Global RNA Therapy Clinical Trials Market, By Phase:

·         Phase I

·         Phase II

·         Phase III

·         Phase IV

  • Global RNA Therapy Clinical Trials Market, By Therapeutic Area:

·         Rare Diseases

·         Anti-infective

·         Anticancer

·         Neurological

·         Alimentary/Metabolic

·         Musculoskeletal

·         Cardiovascular Respiratory

·         Sensory

·         Others

  • Global RNA Therapy Clinical Trials Market, By Region:

·         North America

o   United States

o   Canada

o   Mexico

·         Europe

o   Germany

o   France

o   United Kingdom

o   Italy

o   Spain

·         Asia-Pacific

o   China

o   Japan

o   India

o   South Korea

o   Australia

o   Singapore

·         South America

o   Brazil

o   Argentina

o   Colombia

·         Middle East & Africa

o   UAE

o   Saudi Arabia

o   South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Therapy Clinical Trials Market.

Available Customizations:

Global RNA Therapy Clinical Trials Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global RNA Therapy Clinical Trials Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Types

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, and Trends

4.    Voice of Customer

5.    Global RNA Therapy Clinical Trials Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Modality (RNA interference, Antisense therapy, Messenger RNA, Oligonucleotide, non-antisense, non-RNAi)

5.2.2.    By Phase (Phase I, Phase II, Phase III, Phase IV)

5.2.3.    By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others)

5.2.4.    By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)

5.2.5.    By Company (2022)

5.3.  Product Market Map

5.3.1.    By Modality

5.3.2.    By Phase

5.3.3.    By Therapeutic Areas

5.3.4.    By Region

6.    North America RNA Therapy Clinical Trials Market Outlook

6.1.  Market Size & Forecast       

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Modality

6.2.2.    By Phase

6.2.3.    By Therapeutic Areas

6.2.4.    By Country

6.3.  North America: Country Analysis

6.3.1.    United States RNA Therapy Clinical Trials Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Modality

6.3.1.2.2.           By Phase

6.3.1.2.3.           By Therapeutic Areas

6.3.2.    Canada RNA Therapy Clinical Trials Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Modality

6.3.2.2.2.           By Phase

6.3.2.2.3.           By Therapeutic Areas

6.3.3.    Mexico RNA Therapy Clinical Trials Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Modality

6.3.3.2.2.           By Phase

6.3.3.2.3.           By Therapeutic Area

7.    Europe RNA Therapy Clinical Trials Market Outlook

7.1.  Market Size & Forecast       

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Modality

7.2.2.    By Phase

7.2.3.    By Therapeutic Area

7.2.4.    By Country

7.3.  Europe: Country Analysis

7.3.1.    Germany RNA Therapy Clinical Trials Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Modality

7.3.1.2.2.           By Phase

7.3.1.2.3.           By Therapeutic Area

7.3.2.    France RNA Therapy Clinical Trials Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Modality

7.3.2.2.2.           By Phase

7.3.2.2.3.           By Therapeutic Area

7.3.3.    United Kingdom RNA Therapy Clinical Trials Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Modality

7.3.3.2.2.           By Phase

7.3.3.2.3.           By Therapeutic Area

7.3.4.    Italy RNA Therapy Clinical Trials Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Modality

7.3.4.2.2.           By Phase

7.3.4.2.3.           By Therapeutic Area

7.3.5.    Spain RNA Therapy Clinical Trials Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Modality

7.3.5.2.2.           By Phase

7.3.5.2.3.           By Therapeutic Area

8.    Asia-Pacific RNA Therapy Clinical Trials Market Outlook

8.1.  Market Size & Forecast       

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Modality

8.2.2.    By Phase

8.2.3.    By Therapeutic Area

8.2.4.    By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.    China RNA Therapy Clinical Trials Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Modality

8.3.1.2.2.           By Phase

8.3.1.2.3.           By Therapeutic Area

8.3.2.    Japan RNA Therapy Clinical Trials Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Modality

8.3.2.2.2.           By Phase

8.3.2.2.3.           By Therapeutic Area

8.3.3.    India RNA Therapy Clinical Trials Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Modality

8.3.3.2.2.           By Phase

8.3.3.2.3.           By Therapeutic Area

8.3.4.    South Korea RNA Therapy Clinical Trials Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.           By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.           By Modality

8.3.4.2.2.           By Phase

8.3.4.2.3.           By Therapeutic Area

8.3.5.    Australia RNA Therapy Clinical Trials Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.           By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.           By Modality

8.3.5.2.2.           By Phase

8.3.5.2.3.           By Therapeutic Area

9.    South America RNA Therapy Clinical Trials Market Outlook

9.1.  Market Size & Forecast       

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Modality

9.2.2.    By Phase

9.2.3.    By Therapeutic Area

9.2.4.    By Country

9.3.  South America: Country Analysis

9.3.1.    Brazil RNA Therapy Clinical Trials Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Modality

9.3.1.2.2.           By Phase

9.3.1.2.3.           By Therapeutic Area

9.3.2.    Argentina RNA Therapy Clinical Trials Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Modality

9.3.2.2.2.           By Phase

9.3.2.2.3.           By Therapeutic Area

9.3.3.    Colombia RNA Therapy Clinical Trials Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Modality

9.3.3.2.2.           By Phase

9.3.3.2.3.           By Therapeutic Area

10. Middle East and Africa RNA Therapy Clinical Trials Market Outlook

10.1.             Market Size & Forecast        

10.1.1. By Value

10.2.             Market Share & Forecast

10.2.1. By Modality

10.2.2. By Phase

10.2.3. By Therapeutic Area

10.2.4. By Country

10.3.             MEA: Country Analysis

10.3.1. UAE RNA Therapy Clinical Trials Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Modality

10.3.1.2.2.         By Phase

10.3.1.2.3.         By Therapeutic Area

10.3.2. Saudi Arabia RNA Therapy Clinical Trials Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Modality

10.3.2.2.2.         By Phase

10.3.2.2.3.         By Therapeutic Area

10.3.3. South Africa RNA Therapy Clinical Trials Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Modality

10.3.3.2.2.         By Phase

10.3.3.2.3.         By Therapeutic Area

11. Market Dynamics

11.1.             Drivers

11.2.             Challenges

12. Market Trends & Developments

12.1.             Merger & Acquisition

12.2.             Product Development

12.3.             Recent Developments

13. Competitive Landscape

13.1.             Business Overview

13.2.             Company Snapshot

13.3.             Products & Services

13.4.             Financials (As Reported)

13.5.             Recent Developments

13.5.1. IQVIA Inc

13.5.2. ICON Plc

13.5.3. Laboratory Corporation of America Holdings

13.5.4. Charles River Laboratories International, Inc.

13.5.5. PAREXEL International Corp.

13.5.6. Syneos Health

13.5.7. Medpace Holdings, Inc.

13.5.8. Novotech Inc

13.5.9. Veristat, LLC.

Strategic Recommendations

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global RNA Therapy Clinical Trials Market was estimated to be USD 2.62 billion in 2022.

down-arrow

IQVIA, ICON Plc, Laboratory Corporation of America Holdings, Charles River Laboratories International, Inc., PAREXEL International Corp., Syneos Health, Medpace Holdings, Inc., Novotech, Veristat, LLC, Veristat, LLC. etc are some of the key players operating in the Global RNA Therapy Clinical Trials Market.

down-arrow

Delivery Challenges, Off-Target Effects, Stability and Half-Life are the major challenges faced by the Global RNA Therapy Clinical Trials Market in the upcoming years.

down-arrow

Rapid Advances in RNA Technology, Collaboration and Partnerships and Regulatory Support and Frameworks are majorly driving the growth of the Global RNA Therapy Clinical Trials Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Global RNA Therapy Clinical Trials Market to Grow with a CAGR of 5.06% through 2028

Oct, 2023

The rising growing prevalence of genetic diseases are expected to drive the Global RNA Therapy Clinical Trials Market in the forecast period 2024-2028.

Why Choose Us